To test this hypothesis, we treated 2F8c-Egfl6 tumor-bearing mice with IgG control, a-PD-L1, and Egfl6 NAbs or a combination of Egfl6-NAb and a-PD-L1. This evidence concerns the gene EGFL6 and neoplasm.